Stockscreener 앱 받기
31.65
0.57%
-0.18
전일 마감가:
$31.83
열려 있는:
$32.21
하루 거래량:
465.35K
Relative Volume:
0.46
시가총액:
$3.59B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-14.72
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
-7.91%
1개월 성능:
-7.51%
6개월 성능:
+51.29%
1년 성능:
+35.14%
1일 변동 폭
$31.39
$32.21
1주일 범위
$30.97
$34.87
52주 변동 폭
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
31.65 | 3.61B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily
Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn
First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq
Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq
Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance
Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in NAMS Response - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5%Time to Sell? - MarketBeat
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock near bottom after declineAnalyst Upgrade & Verified Chart Pattern Signals - ulpravda.ru
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from strong economy2025 Historical Comparison & Community Consensus Stock Picks - Улправда
What dividend safety score for NewAmsterdam Pharma Company N.V. stock2025 Technical Patterns & Low Risk High Reward Ideas - Улправда
Louise Frederika Kooij Sells 2,647 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 6,000 Shares of Stock - MarketBeat
Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthEconomic Indicators Overview & Affordable Growth Investments - Улправда
A Look At NewAmsterdam Pharma (NAMS) Valuation As Late Stage CETP Trial Progress Draws Investor Attention - Sahm
NewAmsterdam Pharma (NAMS) Stock Analysis: Unveiling a 43.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3 - Insider Monkey
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners - Investing.com Canada
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4%Time to Sell? - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS - TechStock²
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Behavioral Patterns of NAMS and Institutional Flows - Stock Traders Daily
ID Info Business Services Limited Enters Reversal Setup in Weekly ChartsEconomic Indicators Overview & Target Triple-Digit Stock Opportunities - earlytimes.in
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 43,872 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 26,011 Shares of Stock - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 75,117 Shares - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $928,072.48 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 43,872 Shares of Stock - MarketBeat
Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
How (NAMSW) Movements Inform Risk Allocation Models - Stock Traders Daily
Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - Early Times
EBITDA per share of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView — Track All Markets
Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда
Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn
How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):